Becton, Dickinson and Company (BDX) announced a $110 million investment to expand its BD Neopak™ Glass Prefillable Syringe production in Columbus, Nebraska. The new facility will add capacity for 1 mL and 2.25 mL prefillable syringes, with production expected to begin in mid‑2026.
The expansion will create roughly 120 new jobs and is part of BDX’s broader $2.5 billion U.S. manufacturing investment plan, aimed at strengthening supply‑chain resilience for its pharmaceutical systems portfolio and meeting the growing demand for biologics and GLP‑1 drug delivery.
BDX’s Columbus site has been a manufacturing hub for more than 75 years; the $110 million project follows a recent $35 million expansion that added 50 jobs, underscoring the company’s long‑term commitment to domestic production.
Management highlighted that demand for biologics and GLP‑1s is accelerating, and expanding U.S. manufacturing will support innovation and supply‑chain resilience. “As demand for biologics and GLP‑1s accelerates, BD is strengthening its American manufacturing footprint to support U.S.-based drug delivery innovation and supply chain resiliency,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems.
BDX reported total revenue of $21.84 billion in the last twelve months, up 8.24% year‑over‑year, reflecting strong performance across its pharmaceutical systems portfolio. The new capacity will help sustain that growth trajectory and position BDX to capture a larger share of the high‑margin biologics delivery market.
The $2.5 billion plan covers five years and includes multiple facility upgrades; this $110 million project is a key milestone in that roadmap, positioning BDX to meet U.S. demand and reduce reliance on overseas manufacturing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.